Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record 
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Thailand Inflation Remains Negative for 10th Straight Month in January 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals 
Trump Endorses Japan’s Sanae Takaichi Ahead of Crucial Election Amid Market and China Tensions 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Cresco Labs Inc. and Columbia Care are cannabis and medical marijuana companies that have previously announced their merger through an acquisition deal. In March 2022, they agreed to a transaction that would have created the largest cannabis operator in the United States, but the agreement seems to have gone up in smoke.
Cresco Labs and Columbia made a new announcement on Monday, July 31, stating they have terminated their $2 billion merger deal. This development comes as the industry is waiting for banking reforms, as per CNBC.
Moreover, it was suggested that the contract has been called off as the cannabis industry has been showing indications of a slowdown as it also deals with various economic issues and challenges with regulators. The cannabis companies mutually agreed to scrap their agreement, so there will be no penalties or fees to pay for both parties.
Another reason for the failure of the merger is the fact that Cresco Labs and Columbia Care were not able to unload enough assets required to secure the regulators' seal of approval. They were given the June 30 deadline for this but failed to comply.
"In light of the evolving landscape in the cannabis industry, we believe the decision to terminate the planned transaction is in the long-term interest of Cresco Labs and our shareholders," Cresco Labs' co-founder and chief executive officer, Charles Bachtell, said in a press release.
"We want to express our sincere gratitude to Columbia Care for their valuable collaboration and dedication during this transaction. While this is not the outcome we originally hoped for, we are confident Cresco Labs is in a stronger position moving forward."
Columbia Care's co-founder and CEO, Nicholas Vita, added, "After careful consideration, we are confident in the mutual decision to move forward as separate, standalone companies. This is the best path forward for Columbia Care's employees, customers, and shareholders. We are thankful for the collaboration and partnership with the Cresco team throughout this extensive process."
Photo by: Kimzy Nanney/Unsplash
